Tim Herbert: Got it. Thanks very much. Yeah, there’s a little bit of that carryover from the first quarter. There’s no question about. As we talked about our fourth quarter call that we were on allocation to make sure that we supported every implant that was scheduled, and from that we were able to achieve that, but there’s a little bit of carryover, but even the carryover is relatively small. And even with taking that into account, we were still close to 80% gross — I’m sorry, 80% growth in the quarter, but certainly that exists. Our inventory position is improved and we have that line up and running and ramping. And so we’re able to support all orders right now with positive inventory today and we’re gonna continue to grow that forward.
As far as the number of centers that we experienced, we did get an increase to 68, which is phenomenal. The percent ASCs at this point is now 24% — 24%. So a little bit of an uptick from the prior quarter, which is good because ASCs will continue to grow slightly faster than the hospital setting, which we will continue to grow as well. So I think just opening up the new quarter able to spend some time on opening new centers and that’s why we have that 68 and we’ll continue to be able to scale the number of centers that we open over the quarter. But for the meantime, we’re just leaving our guidance where, where it was.
Operator: Thank you. And I show our next question comes from the line of Adam Maeder from Piper Sandler. Please go ahead.
Adam Maeder: Hi Tim. Hi Rick. Thank you for taking the questions and congrats on the nice start to the year. Wanted to start on a couple of the label expansion opportunities, specifically raising the upper limit of AHI and then also the change to the language around BMI from the current label. Just any latest thoughts on timing and then I had a follow up? Thanks.
Tim Herbert: Absolutely. We’ve been working with the FDA. We answered the question. We’ve passed in the past, we’ve been talking about process, how these PMA supplements go and they’re 180 days, but the FDA asked questions at day 100. We have received the questions, responded to those questions. It’s back in review with the FDA and we see promise moving towards approval and we think that approval is coming in the very near future. I think the high AHI is the really the benefit for patients in that submission member of this submission includes both AHI and BMI. The high AHI, right now those patients just don’t have any other alternative and so that’s a natural fit for them to be able to fit right into Inspire. The limitation really goes back to the early days of the clinical study.
So there’s no reason to really have upper limit on AHI. I also think that we’ll be able to quickly garner reimbursement support or coverage from both commercial payers and Medicare to be able to really take care of that population. We can get those patients approved through the appeal process, but this is going to really streamline their patient experience and be able to get those patients in insurance approval quite quicker. As far as the high BMI, while that presents a good opportunity, it also is something we need to be careful about because remember with the higher BMI, it introduces the concept of lateral wall collapse and that’s what’s very difficult to treat with hypoglossal nerve stimulation. Patients will get improvements because we’ll take care of the tongue-based collapse, but they won’t get a total improvement to the satisfaction that that we desire.
And so we’re going to want those higher BMI patients to address that lateral wall collapse before they’re going to be eligible. That being said, we do have our own work going on and to advance our system to stimulate to take care of lateral wall collapse, but pretty early to talk about that right now.
